Condition: Advanced Breast Cancer · Metastatic Breast Cancer · Triple Negative Breast Cancer (TNBC) · Sponsor: Fudan University
This is a prospective, open-label, phase 2 platform trial. The purpose of this study is to test the safety and effectiveness of the antibody-conjugated drugs (ADCs) in patients with advanced breast cancer who had previously used antibody-conjugated drugs.
This description comes directly from the study's public registry record.
Zhimin Shao, M.D. · 86-21-64175590 · Zhimingshao@yahoo.com
Xiyu Liu, M.D. · 86-21-64175590 · 10301010079@fudan.edu.cn
Always discuss trial participation with your own doctor first.
| Breast cancer institute of Fudan University Cancer Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06649331